Current formula
| Ingredient | Amount | Form |
|---|---|---|
| Ginger | 200 mg | Root powder |
| Boswellia serrata | 100 mg | Gum-resin extract, 65% boswellic acid |
| Hyaluronic acid matrix | 80 mg | HA + polysaccharides + collagen type II matrix |
| Pine bark extract | 150 mg | Pinus pinaster |
| Black pepper | 5 mg | 95% piperine, 50:1 |
Ginger
NCCIH notes that ginger has been studied in several health contexts, while osteoarthritis evidence remains limited or uncertain. Research often uses forms and doses that differ from 200 mg root powder.
Boswellia
The label specifies a 65% boswellic-acid extract. Meta-analyses report improvements in some osteoarthritis outcomes, while NCCIH says stronger evidence is still needed.
Hyaluronic acid matrix / Mobilee®
The label describes 60–80% hyaluronic acid plus polysaccharides and collagen type II. Oral HA and Mobilee have human research, but these are not finished-product Joint Genesis trials.
Pine bark
Some studies use proprietary Pycnogenol®. Because the Joint Genesis label does not identify its 150 mg pine bark as Pycnogenol®, those results are context rather than direct product evidence.
Black pepper / piperine
The label states 95% piperine and identifies BioPerine®. Piperine can influence bioavailability and makes medication-interaction review relevant.
Other ingredients
Cellulose (capsule), magnesium stearate and silica.
Why ingredient form matters as much as ingredient name
Two products can both list “Boswellia” or “pine bark” and still differ substantially. Botanical species, plant part, extraction method, standardization and dose can affect how closely a retail ingredient matches published research. The supplied Joint Genesis label is relatively specific for Boswellia: it identifies Boswellia serrata gum-resin extract at 100 mg and says it is standardized to 65% boswellic acid. The ginger entry, by contrast, is listed as 200 mg of root powder, which should not be assumed equivalent to a concentrated ginger extract used in another trial.
The hyaluronic-acid matrix is listed at 80 mg and provides compositional percentages for hyaluronic acid, polysaccharides and collagen type II. That information is useful for identifying the ingredient, but a label composition is not itself a clinical outcome. The pine bark entry is 150 mg of Pinus pinaster, while the black pepper entry is 5 mg standardized to 95% piperine and described as a 50:1 preparation.
Ingredient evidence is a chain, not a shortcut
For each component, our evidence review asks whether there are human data, whether the studied form resembles the label, what outcomes were measured, how long the studies lasted and whether findings were replicated. A mechanistic explanation—such as a compound participating in normal joint biology or influencing absorption—can make a hypothesis reasonable, but it does not establish that the finished commercial formula will produce a clinically meaningful result.
What the label does not tell us
A Supplement Facts panel does not tell us an individual's response, whether an ingredient will interact with a specific medicine, or whether a symptom has a cause that requires diagnosis. It also does not substitute for a finished-product trial. Those uncertainties are why the research page and safety page are separate pillars rather than marketing footnotes.